Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.51 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341770 | 0.84 | EPHX2 (0.63) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4354102 | 0.84 | TRPV1 (0.58) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4353668 | 0.83 | MAPK1 (0.54) | MAPTMEN1KMT2AHTTLMNA | |
| SCHEMBL4350274 | 0.83 | EPHX2 (0.64) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4349059 | 0.82 | GRIK1 (0.63) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4354878 | 0.82 | MEN1 (0.73) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4357504 | 0.82 | TRPV1 (0.61) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL3706592 | 0.81 | KMT2A (0.75) | MAPTMEN1KMT2ARAB9AHTT | |
| SCHEMBL4348880 | 0.80 | EPHX2 (0.69) | EPHX2MAPTMEN1KMT2ARAB9A | |
| SCHEMBL28729179 | 0.78 | EPHX2 (1.00) | EPHX2MAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| CN-100546977-C | Suppress the new compound and the application thereof of rotamase | JERINI AG (DE) | 2009-10-07 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| CN-1701061-A | Novel compounds for inhibiting rotamase enzymes and uses thereof | JERINI AG (DE) | 2005-11-23 | — | — | CN | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | EPHX2 769/4885MAPT 4439/4885MEN1 2168/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | EPHX2 627/4885MAPT 4184/4885MEN1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.